💊 Pfizer makes a big, big bet on Seagen and its ADC; Sanofi makes a much more modest bet on diabetes; Developed countries bet on exporting pollution
#296 | India’s e-pharmacy laws under review; Space travel for heart tissue; Detecting active TB no longer an issue
Hello, and welcome back to The Kable, where we're still trying to process the sheer magnitude of Pfizer's gambit on Seagen. $43 billion for a company that hasn't turned a profit at last reckoning does seem excessive.
Elsewhere, the GHIT Fund has invested ¥260 million in two Japanese firms, Shionogi and Takeda, for developing new malaria drugs, in partnership with MMV.
New therapies for RSV have been mushrooming a bit lately. GlobalData says this might lead to drug-resistant RSV soon enough.
In the UK, junior doctors have taken up the strike call, kicking off a 3-day walkout yesterday.
In new developments, researchers have developed new tech to easily detect active TB, and a new way to screen virus proteins for antibiotic properties, and, if anyone is still interested, a new therapy for Covid.
And finally, in news that gladdens our heart endlessly, the first of BioNTech's modular vaccine factories has made landfall in Rwanda.